ANL

Adlai Nortye Group Ltd. American Depositary Shares (ANL) | Rumor.io

Adlai Nortye Group

ANL

Attention (50-day avg)0%

Attention rank (50-day avg)#1,765

Bullish sentiment (50-day avg)100%

Price to earnings ratio-13.8

Market capitalization991.7M

Earnings per share-0.66

Dividend yield (TTM)—

Revenue (annual)5M

Net income (annual)-35.5M

Social

What share of all stock conversation is about ANL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Apr 16

Adlai Nortye Ltd. American Depositary Shares (ANL) announced a $150.0 million private placement equity financing with participation from top-tier institutional investors.
The private placement includes 11.3M ADSs at $13.25 per ADS, reinforcing confidence in ANL's RAS-targeting pipeline and RASiCA ADC.
ANL's shares gapped +18% on the news, with strong institutional demand signaling conviction in the clinical-stage pipeline.

Generated by AI

Sentiment

Of the messages about ANL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	89.62% +2.96
Bearish	—	0%	0% 0	10.38% -2.96

Bullish· Feb 3

$ANL has impressive strength, with price refusing to pull back and buyers remaining aggressive, indicating a strong uptrend.
Adlai Nortye's recent $140M private placement at a price under $7 is a bargain, providing a significant boost to the company's war chest.
$ANL's consolidation above $11, with a potential bullish pennant forming, suggests a breakout could be imminent if the price clears this consolidation zone with strength.

Bearish· Dec 29

The majority of the selling in $ANL has occurred, but shorts haven't started closing, and there are no buyers to drive the price up.
$ANL's financial reality is concerning, with a net loss of $18.3M for 6 months, cash burn, and a thin buffer of shareholders' equity.
The ASK Pharm licensing deal is not as promising as it seems, with most of the consideration conditional and in the future, and an upfront cash payment small relative to losses and market cap.

Generated by AI

Topics

Of the messages about ANL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	80.87%	55.67%
Technical Analysis	—	100%	5.22%	16.93%
Analysts	—	0%	13.91%	14.26%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	13.14%

Announcements· Feb 3

Adlai Nortye Ltd. American Depositary Shares (ANL) has announced a $140.0 million private placement equity financing.
The financing is expected to result in gross proceeds of approximately $140.0 million, before deducting placement agent fees and other expenses.
The private placement is expected to bolster the balance sheet of Adlai Nortye, a clinical-stage biotech developing next-gen cancer therapies, for cancer therapy development.

Macro· May 31

The Intel Aurora supercomputer's delivery is delayed, with the current timeline indicating a completion date of late 2021 or early 2022.
The supercomputer's performance is expected to be 1.0 exaflops, a significant upgrade from the original plan.
The delay and performance upgrade have implications for the development and deployment of exascale computing, with the Frontier supercomputer at Oak Ridge National Laboratory set to be the first to achieve this level of performance.

Technical Analysis· Jan 29

ANL has shown a wild move in China, with a potential breakout above 4.5-4.75 and a bounce in vwap.
The stock is holding near highs, with buyers remaining active and momentum remaining bullish, suggesting a potential rally from the current base.
Key levels to watch include the 52-week high of $4.20, the 9.27 level, and the 11.10 level, which are being seen as critical support and resistance points.

Generated by AI

Community

Of the messages about ANL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	39.87%	19.63%
Newcomers	—	100%	60.13%	80.38%

Apr 16

Adlai Nortye Ltd. American Depositary Shares ($ANL) has announced a $150.0 million private placement equity financing with participation from top-tier institutional investors.
The private placement includes 11.3M ADSs at $13.25 per ADS, reinforcing confidence in ANL's RAS-targeting pipeline and RASiCA ADC technology.
Strong institutional demand signals conviction in the clinical-stage pipeline, with investors such as Soleus Capital, Perceptive Advisors, and ADAR1 participating in the oversubscribed private placement.

Generated by AI

Why the AN4035 trial move matters for Adlai Nortye Group stock Adlai Nortye Group (NasdaqGM:ANL) has just dosed the first patient in its global Phase I trial for AN4035 and secured a Study May Proceed letter from the FDA, clearing expansion into the United States. The fresh AN4035 milestone comes after a strong run in Adlai Nortye Group’s stock, with a very large year-to-date share price return and a 1-year total shareholder return of about 8x. Recent 30-day and 90-day share price returns of...

14d agoYahoo Finance

Jefferies initiates Adlai Nortye stock with buy rating on drug potential

20d agoInvesting.com

Jefferies Initiates Coverage on Adlai Nortye With Buy Rating, $31 Price Target

Adlai Nortye (ANL) has an average rating of buy and mean price target of $28.60, according to analys

20d agofinance.yahoo.com

Adlai Nortye: A Deep Dive (NASDAQ:ANL)

20d agoSeeking Alpha

Also Discussed

Investors talking about ANL also mention

#	Name	Attention
1	CUK - Carnival Corporation & plc	——
2	Erasca Inc.ERAS	0%0
3	PP - The Meet Kevin Pricing Power ETF	——
4	Virtus LifeSci Biotech Clinical Trials ETFBBC	0%0
5	IPVF - InterPrivate III Financial Partners Inc.	——
6	AZZ Inc.AZZ	0%0
7	Brand Engagement Network Inc.BNAI	0%+0
8	VERO - Venus Concept Inc.	——
9	FAT Brands Inc. Class B Common StockFATBB	0%0
10	Global Interactive Technologies, Inc.GITS	0%0

Adlai Nortye Group Ltd. American Depositary Shares

Healthcare
Biotechnology

Adlai Nortye Group Ltd. American Depositary Shares is the U.S.-traded share class of Adlai Nortye Ltd., a clinical-stage biotechnology company focused on developing cancer therapies. The company’s current work centers on advancing oncology drug candidates through clinical research, with programs spanning targeted treatments designed to address different tumor types and treatment settings. Its portfolio includes investigational therapies aimed at modulating key cancer pathways and the tumor microenvironment, reflecting a focus on precision medicine approaches in oncology. Adlai Nortye serves as a small but active participant in the global biopharmaceutical market, with operations connected to drug discovery, preclinical development, and late-stage clinical testing. The American Depositary Shares give U.S. investors access to the company’s ordinary shares through a structure commonly used by international life sciences firms.

Website

Location

77 Robinson Road

Singapore, NJ, 068896

Singapore

Social

What share of all stock conversation is about ANL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Apr 16

Adlai Nortye Ltd. American Depositary Shares (ANL) announced a $150.0 million private placement equity financing with participation from top-tier institutional investors.
The private placement includes 11.3M ADSs at $13.25 per ADS, reinforcing confidence in ANL's RAS-targeting pipeline and RASiCA ADC.
ANL's shares gapped +18% on the news, with strong institutional demand signaling conviction in the clinical-stage pipeline.

Generated by AI

Sentiment

Of the messages about ANL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	89.62% +2.96
Bearish	—	0%	0% 0	10.38% -2.96

Bullish· Feb 3

$ANL has impressive strength, with price refusing to pull back and buyers remaining aggressive, indicating a strong uptrend.
Adlai Nortye's recent $140M private placement at a price under $7 is a bargain, providing a significant boost to the company's war chest.
$ANL's consolidation above $11, with a potential bullish pennant forming, suggests a breakout could be imminent if the price clears this consolidation zone with strength.

Bearish· Dec 29

The majority of the selling in $ANL has occurred, but shorts haven't started closing, and there are no buyers to drive the price up.
$ANL's financial reality is concerning, with a net loss of $18.3M for 6 months, cash burn, and a thin buffer of shareholders' equity.
The ASK Pharm licensing deal is not as promising as it seems, with most of the consideration conditional and in the future, and an upfront cash payment small relative to losses and market cap.

Generated by AI

Topics

Of the messages about ANL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	80.87%	55.67%
Technical Analysis	—	100%	5.22%	16.93%
Analysts	—	0%	13.91%	14.26%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	13.14%

Announcements· Feb 3

Adlai Nortye Ltd. American Depositary Shares (ANL) has announced a $140.0 million private placement equity financing.
The financing is expected to result in gross proceeds of approximately $140.0 million, before deducting placement agent fees and other expenses.
The private placement is expected to bolster the balance sheet of Adlai Nortye, a clinical-stage biotech developing next-gen cancer therapies, for cancer therapy development.

Macro· May 31

The Intel Aurora supercomputer's delivery is delayed, with the current timeline indicating a completion date of late 2021 or early 2022.
The supercomputer's performance is expected to be 1.0 exaflops, a significant upgrade from the original plan.
The delay and performance upgrade have implications for the development and deployment of exascale computing, with the Frontier supercomputer at Oak Ridge National Laboratory set to be the first to achieve this level of performance.

Technical Analysis· Jan 29

ANL has shown a wild move in China, with a potential breakout above 4.5-4.75 and a bounce in vwap.
The stock is holding near highs, with buyers remaining active and momentum remaining bullish, suggesting a potential rally from the current base.
Key levels to watch include the 52-week high of $4.20, the 9.27 level, and the 11.10 level, which are being seen as critical support and resistance points.

Generated by AI

Community

Of the messages about ANL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	39.87%	19.63%
Newcomers	—	100%	60.13%	80.38%

Apr 16

Adlai Nortye Ltd. American Depositary Shares ($ANL) has announced a $150.0 million private placement equity financing with participation from top-tier institutional investors.
The private placement includes 11.3M ADSs at $13.25 per ADS, reinforcing confidence in ANL's RAS-targeting pipeline and RASiCA ADC technology.
Strong institutional demand signals conviction in the clinical-stage pipeline, with investors such as Soleus Capital, Perceptive Advisors, and ADAR1 participating in the oversubscribed private placement.

Generated by AI

Adlai Nortye Group

Social

Apr 16

Bullish· Feb 3

Bearish· Dec 29

Announcements· Feb 3

Macro· May 31

Technical Analysis· Jan 29

Apr 16

Adlai Nortye director Ji Ping sells $83,150 in shares

Adlai Nortye at Morgan Stanley global healthcare conference: RAS push

4.8x P B? Adlai Nortye Group (ANL) On Its AN4035 Trial Progress

Jefferies initiates Adlai Nortye stock with buy rating on drug potential

Jefferies Initiates Coverage on Adlai Nortye With Buy Rating, $31 Price Target

Adlai Nortye: A Deep Dive (NASDAQ:ANL)

Also Discussed

Adlai Nortye Group Ltd. American Depositary Shares

Company Information

Location

Social

Apr 16

Bullish· Feb 3

Bearish· Dec 29

Announcements· Feb 3

Macro· May 31

Technical Analysis· Jan 29

Apr 16

Adlai Nortye director Ji Ping sells $83,150 in shares

Adlai Nortye at Morgan Stanley global healthcare conference: RAS push

4.8x P B? Adlai Nortye Group (ANL) On Its AN4035 Trial Progress

Jefferies initiates Adlai Nortye stock with buy rating on drug potential

Jefferies Initiates Coverage on Adlai Nortye With Buy Rating, $31 Price Target

Adlai Nortye: A Deep Dive (NASDAQ:ANL)

Also Discussed